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Abstract 
Adequate drug distribution through tumours is essential for treatment to be effective. 
Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor approved for use in patients with 
hormone receptor (HR) positive, HER2 negative metastatic breast cancer (BC). It has 
unusual physicochemical properties, which may significantly influence its distribution in 
tumour tissue. We studied the penetration and distribution of palbociclib in vitro, including the 
use of multicellular three-dimensional models and mathematical modelling. MCF-7 and DLD-
1 cell lines were grown as single cell suspensions (SCS) and spheroids; palbociclib uptake 
and efflux were studied using liquid chromatography-tandem mass spectrometry (LC-
MS/MS). Intracellular concentrations of palbociclib for MCF-7 SCS (Cmax 3.22µM) and 
spheroids (Cmax 2.91 µM) were 32 and 29 fold higher and in DLD-1, 13 and 7 fold higher, 
respectively than the media concentration (0.1 μM). Total palbociclib uptake was lower in 
DLD-1 cells than MCF-7 cells both in SCS and in spheroids. Both uptake and efflux of 
palbociclib were slower in spheroids than SCS. These data were used to develop a 
mathematical model of palbociclib transport that quantifies key parameters determining drug 
penetration and distribution. The model reproduced qualitatively most features of the 
experimental data and distinguished between SCS and spheroids, providing additional 
support for hypotheses derived from the experimental data. Mathematical modelling has the 
potential for translating in vitro data into clinically relevant estimates of tumour drug 
concentrations.  
 
Significance statement 
This study explores palbociclib uptake and efflux in single cell suspension and spheroid 
models of cancer. Large intracellular concentrations of palbociclib are found after drug 
exposure. The data from this study may aid understanding of the intratumoural 
pharmacokinetics of palbociclib which is useful in understanding how drug distributes within 
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tumour tissue and optimising drug efficacy. Bio-mathematical modelling has the potential to 
derive intratumoural drug concentrations from plasma pharmacokinetics in patients. 
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Introduction 
For cancer therapeutics to be effective, drug concentrations must exceed a threshold level 
within cancer cells for a period of time sufficient to ensure the desired effect. 
Pharmacokinetic resistance, the ineffective delivery of the drug to the cell, has been 
recognised as an important contributor to treatment failure (Minchinton and Tannock, 2006). 
The tumour microstructure plays an important role in pharmacokinetic resistance, since 
cancer drugs have to penetrate and distribute throughout the tumour to be optimally effective 
(Minchinton and Tannock, 2006). The physicochemical properties of each drug also 
influences its delivery and distribution; the molecular weight, polarity, pKa and extent of 
protein binding of a drug all affect how it distributes within the tumour (Fuso Nerini et al., 
2014). 
Most preclinical intratumoural pharmacokinetic (PK) data relate to cytotoxicity testing in vitro, 
using measures such as IC50, and plasma PK in vivo; the majority of preclinical drug 
distribution studies focus on distribution within individual organs rather than tumours. 
Although there is a trend to investigate drug penetration using  in vitro tissue models in pre-
clinical drug development (Katt et al., 2016), these studies are not usually routinely 
performed. In vitro multicellular models using cancer cells are feasible and potentially useful 
to answer questions around drug penetration and distribution at a tissue or cellular level 
(Barrera-Rodríguez and Fuentes, 2015; Evans et al., 2009; Winter et al., 2019). Multicellular 
models have been used previously to study intratumoural drug penetration (Godugu et al., 
2013; Huang and Gao, 2018). Moreover, some of the PK parameters derived from such 
models can be used to develop biomathematical models that can improve the understanding 
of key factors which govern intratumoural drug delivery (Evans et al., 2009; Groh et al., 
2014). These models are limited by the parameters obtained from experiments but can 
potentially optimize the drug development process by identifying promising drug 
combinations and schedules, supplementing in vivo studies which are resource intensive 
and involve ethical issues, so are limited in number (Altrock et al., 2015).  
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Once a drug enters clinical trials, plasma PK studies are routine, but there are few drugs for 
which intratumoural drug concentrations and/or distribution have been studied. One 
exception is the fluoropyrimidine pro-drug capecitabine, where a PK study confirmed 
preferential conversion to 5-FU in the tumour (Schüller et al., 2000).  
Palbociclib (Ibrance®, Pfizer) is an oral cyclin-dependent kinase (CDK) 4/6 inhibitor that 
blocks phosphorylation of the retinoblastoma (Rb) protein, a tumour suppressor that controls 
the transition from G1 to S phase of the cell cycle. Palbociclib, and other CDK4/6 inhibitors, 
are approved in combination with endocrine therapy in patients with hormone receptor (HR) 
positive, HER2 negative metastatic breast cancer (BC) (EMA, 2016; Pfizer, 2015), in whom 
the combination approximately doubles progression-free survival (Clark et al., 2016). 
Palbociclib has unusual physicochemical properties, which are likely to have a significant 
influence on its penetration and distribution through tissues. Namely, it has a very large 
volume of distribution of 2583L and a half-life of 26h, indicating extensive drug binding to 
peripheral tissues (Flaherty et al., 2012; Schwartz et al., 2011). Furthermore, in whole blood 
palbociclib distributes preferentially into the cellular component over plasma, with a whole 
blood to plasma concentration ratio of 1.63 (EMA, 2016). Separate studies have reported 
plasma palbociclib PK (Smith et al., 2011) and intratumoural palbociclib concentrations in 
vivo (Nguyen et al., 2010) but were based on different doses and routes of administration. 
Reported clinical plasma concentrations for palbociclib range from 0.062μM to 0.278μM 
(FDA, 2014; Masuda et al., 2018; Tamura et al., 2016; Taylor et al., 2018). Studies have not 
reported a direct comparison of both intratumoural and plasma palbociclib concentrations, 
except in the case of glioblastoma where the issue is complicated by the blood brain barrier 
(Taylor et al., 2018). 
Better understanding of intratumoural palbociclib PK may inform the design of new clinical 
trials. For example, in studies combining cell cycle inhibitors with chemotherapy, cell cycle 
arrest may reduce the efficacy of chemotherapy leading to antagonistic rather than 
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synergistic effects (Dean et al., 2012; McClendon et al., 2012); alternative dosing or 
scheduling may overcome such a limitation.  
We have developed a methodology to study drug uptake and efflux in SCS and 3D spheroid 
models, quantifying drug concentrations using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). This allows us to explore the ability of the drug to move through 
single cells and spheroids. Using these data, we have developed a mathematical model of 
palbociclib transport through cancer cells that can quantify the role of key parameters which 
determine drug penetration and distribution within the tumour. 
 
2. Materials and Methods 
2.1. LC-MS/MS methodology:  
Stock solutions of palbociclib were prepared at 1 mM in DMSO and stored at -20 ºC. 
Standard solutions for system calibration were made by further dilutions of stock solutions 
with a mixture of 50 % mobile phase A (MPA) and 50 % mobile phase B (MPB). For each set 
of experiments run on LC-MS/MS, calibration curves were created between 0.02 and 10 μM. 
Samples were separated and analysed on a Waters 2695 HPLC system in combination with 
a Waters 2996 Diode Array Detector and a Waters Micromass Ultima triple quadrupole MS. 
Samples were maintained at 4 ºC in the auto-sampler and 10 µL injected for analysis. 
Sample separation was carried out on a HiChrom RPB column (250 x 2.1 mm id, 5 µm 
particle size) maintained at 40 ºC. Gradient elution was applied with 10 % acetonitrile 
(MeCN) and 0.1 % formic acid for MPA, and 50 % MeCN and 0.1 % formic acid for mobile 
phase B (MPB) with the following gradient: the starting eluent consisted of 70 % MPA and 30 
% MPB, the proportion of MPB increasing linearly to 80 % over 5 min and then returning to 
30 % over 1 min. The column was re-equilibrated at starting conditions for 4 min. The flow 
rate was 0.5 ml min-1, and split post-column with 0.3 ml min-1 delivered to the MS. Palbociclib 
was detected by monitoring the mass transition m/z 448.73 > 381.04 with the instrument 
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operating in positive mode. A cone energy of 20 eV and collision energy of 20 eV was used 
with argon gas as the collision gas. The UV signal of palbociclib was also monitored at a 
wavelength of 365 nm. 
2.2. Cell culture:  
The human breast cancer cell line MCF-7 and the human colorectal cancer cell line DLD-1 
were obtained from our laboratory. Cell line provenance was verified by annual STR profiling 
(European Collection of Authenticated Cell Cultures [ECACC], Public Health England, 
Porton Down, Salisbury, UK) and bi-monthly mycoplasma testing was regularly undertaken 
in house using a MycoProbe Mycoplasma Detection Kit (R&D Systems, Inc, Minneapolis, 
USA). Both cell lines have the capability to form spheroids.  
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose, 
supplemented with 10 % foetal bovine serum and 5 % L-Glutamine. For MCF-7 cell line, 1 % 
insulin was also added. Spheroids were created using 96-well plates previously coated with 
1 % Agarose. We optimized spheroid formation to achieve a diameter of approximately 400 
µm on day 4 (collecting day) by seeding at 3500 cells ml-1 for MCF-7 and 6000 cells ml-1 for 
DLD-1. Spheroid diameter was optimized to avoid the formation of a necrotic core and 
reduce variability in the subsequent assays. Briefly, spheroids were embedded in paraffin, 
sectioned and stained with haematoxylin-eosin to visualize their structure and confirm the 
absence of a necrotic core (Supplementary Figure S3).  Cells were maintained in 25 ml 
tissue culture flasks at 37 ºC in humidified incubator with 5 % CO2. 
2.3. Cell viability: 
Both MCF-7 and DLD-1 were treated for 480 min with 0.1 µM of palbociclib, under the 
conditions described below for both uptake and efflux experiments, with viable cells counted 
using a haemocytometer and trypan blue.  
2.4. Western blots: 
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We performed western blots of retinoblastoma (Rb), phospho-retinoblastoma (pRb; serine 
780), CDK4 and CDK6 as a pharmacodynamics measure of whether palbociclib’s 
mechanism of action was preserved in the cell lines.  
MCF-7 and DLD-1 cells were grown as described above and, once confluent, harvested for 
analysis. Cell pellets were lysed for 10 min on ice in buffer containing a protease and 
phosphatase inhibitor cocktail mix (Abcam), followed by sonication using 3 x 5 second cycles 
twice at 40 % power. Samples were tested for protein content by Bradford assay and loaded 
on to 10 % SDS-polyacrylamide gels at 50 μg well-1 protein for separation. A protein ladder 
was also loaded for molecular weight comparison (PageRuler Plus Prestained Protein 
Ladder, Fermentas Life Sciences). Separated proteins were then transferred onto a 
nitrocellulose membrane and incubated with blocking buffer appropriate to the 1° antibody 
(Ab) for 1 h. Membranes were subsequently incubated with the following 1°Abs overnight at 
4°C: CDK4 (D9G3E) Rabbit mAb, CDK6 (DCS83) Mouse mAb, Rb (4H1) Mouse mAb, 
Phospho-Rb (Ser780) (D59B7) Rabbit mAb, Phospho-Rb (Ser795) Ab and Phospho-Rb 
(Ser807/811) (D20B12) XP Rabbit mAb. β-Actin Ab was used as a control. Following 
incubation with the appropriate 2°Ab for 1 h at room temperature, the membranes were 
incubated with SignalFire ECL Reagent (Cell Signaling Technology Inc.) for 1 min and the 
signal captured on x-ray film. Exposure time varied from 10 s to 3 min, depending on the 
antibody used. 
2.5. In vitro drug uptake and efflux: 
The palbociclib concentration used for uptake and efflux experiments was 0.1 µM.  This 
dose was selected based on reported clinical plasma concentrations (FDA, 2014; Masuda et 
al., 2018; Tamura et al., 2016; Taylor et al., 2018). A concentration at the lower end of the 
range was chosen to assure cell viability whilst remaining above the biologically effective 
dose of 0.06 µM (FDA, 2014).   
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2.5.1. Drug uptake:  
One million cells in suspension, or 30 spheroids per time point, were maintained at 37 ºC in 
Eppendorfs and treated with 1ml of 0.1 µM palbociclib in complete media for 0 to 240 min (0, 
5, 10, 20, 40, 60, 120 and 240 min) and 0 to 480 min (0, 5, 10, 20, 40, 60, 120, 240, 360 and 
480 min), respectively. At each designated time point, cells were centrifuged at 1000 g for 2 
min, media discarded and the cell pellet or spheroids washed three times with phosphate-
buffered saline (PBS) before re-suspension in 150 µl of acetonitrile and storing on ice.  The 
cell pellet or spheroids were sonicated twice at 40% power for three x 5 second cycles and 
six x 5 second cycles, respectively using a Sonoplus HD2070 Homogeniser Ultrasonic 
(Scientific Laboratory Supplies Limited, UK) to disrupt the cell membranes and release 
intracellular drug. All samples were then centrifuged at 10,000 g for 5 min. Finally the 
supernatant was transferred to a new Eppendorf and evaporated using a Genevac personal 
evaporator at 37 ºC, 8 mbar pressure for approximately 120 min and reconstituted in 30 µl of 
mobile phase (MPA:MPB, 1:1). Appropriate control samples of untreated cells or spheroids 
and samples containing drug without cells were also included to ensure the validity of the 
assay. The method is described in Supplementary Figure S1. 
 
2.5.2. Drug efflux:  
One million cells in suspension or 30 spheroids were treated with 1 ml of 0.1 µM palbociclib 
in complete media for 1 hour and 2 hours, respectively at 37 ºC. After incubation with drug, 
samples were centrifuged at 1000 g for 2 min, media containing drug removed and the cell 
pellet or spheroids washed three times with PBS.  50 µl of fresh drug-free media was then 
added and samples incubated for 5 to 240 min (5, 10, 20, 40, 60, 120 and 240 min) and 5 to 
480 min (5, 10, 20, 40, 60, 120, 240, 360 and 480 min) for cells and spheroids, respectively. 
At each designated time point, samples were centrifuged for 2 min at 1000 g and the media 
transferred to a clean Eppendorf.  Both media and cell or spheroid pellets were processed 
for analysis as described above. The method is described in Supplementary Figure S2. 
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Protein concentration for each experiment was measured using the Bradford assay. Cell and 
spheroid volumes were derived from their respective diameters assuming both to be 
spherical. Diameters were measured accurately using a metric rule under the microscope at 
20x and validated by Image J software for scientific analysis. For single cell diameters, at 
least 50 cell diameters were measured in different passages; the mean cell diameter was 
used to derive the cell volume. For spheroids, the diameter of 15 spheroids was measured in 
each experiment and the mean diameter used to calculate the spheroid volume. Each 
experiment was performed in triplicate. 
2.6. Data analysis:  
SCS and spheroid pellets were diluted at the end of the experiment in 30 µl MPA. To 
determine the actual concentration of drug in the cell or spheroid pellets the following 
equation applied (all volumes in µl):  
SCS 
Dilution factor = [(volume of a single cell x 1x106 cells) + 30 µl] / volume of a single cell x 
1x106 cells   
Spheroids 
Dilution factor = [(volume of a spheroid x 30 spheroids) + 30 µl] / volume of a spheroid x 30 
spheroids. 
We also expressed drug concentrations relative to the sample protein concentration for each 
experiment (drug concentration:protein ratio), which is independent of cell or spheroid 
volume. 
Raw LC-MS data were processed in MassLynx V4.1. and graphs plotted in Graph Pad 
PRISM 6.  
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2.7.  Statistics: 
 
Statistical comparison of PK parameters (e.g. area under the concentration-time curve; total 
drug uptake/efflux [AUC], maximum concentration [Cmax], time at which maximum 
concentration is observed [Tmax] and rate of uptake/efflux) between cells and spheroids were 
made using Graph Pad PRISM 6. Both Cmax and Tmax were derived from direct observation of 
GraphPad PK curves. All graphs were represented with mean plus error bars with three 
independent data points per time point, therefore we consider that representing descriptive 
data was more appropriate. Experiments were performed in triplicate which precludes the 
assumption of a normal distribution of the data, the Mann-Whitney U test was, therefore, 
used for statistical comparisons. We used coefficient of variation (CV) to determine the 
technical error of drug uptake and efflux experiments. Technical error was tested performing 
three repeats in SCS at the 60 min drug uptake time point with a CV of 19.4% and in SCS at 
the 6 hour drug efflux time point with a CV of 32.5%. 
2.8. Mathematical modelling: 
The mathematical model used to describe the transport of palbociclib in single cells and in 
spheroids has been described previously (Hubbard et al., 2017). In summary, the interaction 
of palbociclib with the microenvironment of cells is restricted to drug binding, and described 
by a three-compartment model, comprising extracellular space (volume V1, 1ml for uptake 
experiments, 50μl for efflux experiments) with a uniform concentration C1 of free drug, and 
intracellular space (volume V2, 1.65μl for DLD-1 and 3.28μl for MCF-7) with concentrations 
C2 and C3 corresponding to free and bound drug respectively. The term “bound” refers to all 
types of binding taking place within the cell, including to protein, lipids and organelles. It is 
assumed that binding can be described by a simple kinetic model with drug binding 
reversibly to sites within the cell. The core model equations are given by: 
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where a is the total cellular surface area (6.75×10-4 m2 for DLD-1, 1.07×10-3 m2 for MCF-7 
cells). These equations contain four parameters that are found using a least-squares fit to 
the experimental data – these are k1, the rate of transport across the cell membrane, k2, the 
binding rate, k-2, the unbinding rate, and C0, the concentration of binding sites in the cells. 
The model adopts a compartmental approach in which it is assumed that there is a rapid 
equilibration of concentration within the extracellular volume and that, for SCS, the free and 
bound fractions of drug are evenly distributed within the intracellular compartment. For 
spheroid modelling we no longer assume that equilibration of drug throughout the spheroid is 
instantaneous but instead model the spatial variation of drug concentration within the 
spheroid using diffusive transport. The spheroid model is derived by means of a multiscale 
homogenisation technique developed previously (Babuška, 1976; Larsen, 1975; Sanchez-
Palencia, 1970), and recently applied to relevant biological contexts (Dalwadi, 2018; Shipley 
and Chapman, 2010). Full details of the analysis (Supplementary material, Annex 2) is 
described by Holden, 2018 (Holden, 2018). In brief, this allows for the derivation of a 
macroscale description of the drug dynamics, based on the kinetic model, which 
accommodates microscale features of drug transport and binding kinetics. 
The spheroid model introduces an additional parameter that represents a diffusion rate, the 
value of which is found with the other four parameter values using a least-squares fit to the 
spheroid data (Supplementary material, Annex 1). The numerical model divides the spheroid 
into a series of concentric layers and it is assumed that the dynamics of drug transport can 
be attributed to the exchange of free drug between these layers in the spheroids and 
between the extra- and intra-cellular compartments, and binding/unbinding within the 
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intracellular compartment. In line with the experimental procedure described above, the 
parameter-fitting procedure is undertaken for modelling the uptake of drug by initially drug-
free cells, and for modelling the efflux of drug from cells initially bathed in drug. The model 
parameters are estimated for each cell line by fitting to all six available datasets at once 
(intracellular uptake and intra- and extracellular efflux for both single cells and spheroids).  
2.9. Materials:  
Palbociclib (PD 0332991), agarose, phosphate-buffered saline, cell culture reagents, DMSO 
and HPLC grade acetonitrile, water, and formic acid, were all purchased from Sigma-Aldrich, 
UK. For western blotting all antibodies were purchased from Cell Signalling Technology Inc; 
all other reagents were purchased from Sigma-Aldrich, UK unless otherwise specified. 
 
3. Results 
3.1. Cell viability assay and western blot: 
Cytotoxic activity for palbociclib has not previously been reported in vitro; to ensure cell 
death did not influence uptake and efflux values obtained in our experiments, the cells were 
first tested for viability. MCF-7 and DLD-1 cell lines were treated at 0.1 µM of palbociclib for 
480 min under the same conditions as those to be used for the uptake and efflux 
experiments; 98% and 97% of cells were viable for MCF-7 and DLD-1, respectively following 
incubation with drug. 
To account for potential variability between cell lines in uptake/efflux due to binding to the 
drug target, we tested expression of CDK4 and downstream signalling proteins in the cell 
lines by performing western blots of retinoblastoma (Rb), phospho-retinoblastoma (pRb) 
(serine 780), CDK4 and CDK6. Both cell lines were positive for Rb (110kDa), pRb (110kDa) 
and CDK4 (30kDa) and negative (i.e. below detectable levels) for CDK6 (37kDa). The MCF-
7 cell line had higher CDK4 expression than the DLD-1 cell line (Figure 1). A positive blot for 
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CDK6 in HCC38, a breast cancer cell line, is shown in the Supplementary Figure S4 as a 
positive control.   
 
3.2. Uptake: 
Uptake of palbociclib into SCS and spheroids over time was measured in MCF-7 and DLD-1 
cell lines (Figure 2A & B, Table 1). In the SCS, the initial rate of change of intracellular 
concentration was 631.1 and 187.3 nM min-1 for MCF-7 and DLD-1, respectively. In contrast, 
in spheroids the initial rate of uptake (log phase) was 31.2 and 15.6 nM min-1 for the MCF-7 
and DLD-1 lines, respectively. In SCS the Cmax of intracellular palbociclib was reached at 10 
min then plateaued, whereas in spheroids uptake did not achieve steady state until 120 min 
in DLD-1 and 240 min in MCF-7, respectively. The intracellular palbociclib Cmax was far 
higher than the concentration in the external media, in both cells and spheroids. In MCF-7 
the mean Cmax was 3.22 µM in SCS and 2.91 µM in spheroids; this was 32 and 29 fold 
higher, respectively, than the treatment concentration of 0.1 µM. In the DLD-1 cell line the 
mean Cmax in SCS was 1.28 µM, and 0.68 µM in spheroids; this is almost 13 and 7 fold 
higher, respectively, than the external media concentration. The difference, in Cmax between 
SCS and spheroids was not, however, statistically significant (Mann-Whitney test p=0.36 for 
MCF-7 line and p=0.2 for DLD-1 line). Moreover, Cmax was higher in the MCF-7 line than in 
DLD-1 in both SCS and spheroids; the difference was statistically significant only in SCS 
(Mann-Whitney test: p= 0.035 for SCS and 0.1 for spheroids).  
Total palbociclib uptake, expressed as AUC taken from the drug uptake curve, was lower in 
DLD-1 (mean AUC(0-4h) 169 µM.h and 119 µM.h for SCS and spheroids, respectively) than in 
MCF-7 experiments (mean AUC(0-4h) 509 µM.h and 368 µM.h  for SCS and spheroids, 
respectively); this difference reached statistical significance in SCS but not the spheroids 
(Mann-Whitney test: p=0.035 and 0.1, respectively). These results did not differ significantly 
when expressed as drug:protein ratio, with a similar pattern of drug uptake reaching Cmax at 
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10 min in SCS for both cell lines, and at 120 min for DLD-1 and 240 min for MCF-7 
spheroids (Supplementary Figure S5).  
The initial rate of uptake (log phase) was 10.29 and 2.25 pmol mg-1 min-1 for the MCF-7 and 
DLD-1 SCS, respectively. In spheroids the initial rate of uptake (log phase) was 0.29 and 
0.10 pmol mg-1 min-1 for the MCF-7 and DLD-1 lines, respectively. Mean Cmax in MCF-7 was 
53.5 pmol mg-1 for SCS and 31.6 pmol mg-1 for spheroids. DLD-1 mean Cmax was 15.29 pmol 
mg-1 and 8.11 pmol mg-1, for cells and spheroids respectively. Total palbociclib uptake, 
expressed as mean AUC(0-4h), for the uptake curve in DLD-1 was 2440 h.pmol mg-1 and 1510 
h.pmol mg-1 for SCS and spheroids, respectively, and for MCF-7 was 7535 h.pmol mg-1 and 
4689 h.pmol mg-1  for SCS and spheroids, respectively. The differences in palbociclib uptake 
of SCS between DLD-1 and MCF-7 for Cmax and AUC did not reach statistical significance 
when expressed as drug:protein ratio (p=0.057 and p=0.057, respectively).  
 
3.3. Efflux: 
Efflux of palbociclib from cells and spheroids was measured over time after one and two 
hours respectively of drug exposure in MCF-7 and DLD-1 cell lines (Figure 3, Table 2). Drug 
exposure time prior to efflux experiments was selected based on the time taken to reach 
Cmax in uptake experiments. Exposure time was, therefore, longer in spheroids as drug 
uptake was slower. This ensured the initial intracellular drug concentration was close to 
steady state before efflux commenced and limited the potential for experimental error.   
The rate of change of intracellular concentration of palbociclib during efflux studies in SCS 
and spheroids was -2.3 and -2.1 nM min-1, respectively in the MCF-7 cell line. In the DLD-1 
cell line palbociclib efflux was -0.08 and -0.1 nM min-1, respectively in SCS and spheroids.  
In MCF-7, efflux equilibrium was achieved somewhat later than in the DLD-1. In SCS efflux 
equilibrium was reached at 480 min in MCF-7 and 240 min in DLD-1. In spheroid efflux, 
DLD-1 reached equilibrium at 240 to 360 min, whilst MCF-7 had not yet reached equilibrium 
by 480 min (the latest time point measured). Again, these results were similar when 
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expressed as drug to protein ratio (Supplementary Figure S6). The ratio of intracellular to 
extracellular drug was calculated at each time point (Supplementary Figure S7). In MCF-7 
the percentage of intracellular palbociclib remaining at 480 min was 45.14% and 70.76% in 
the SCS and spheroids, respectively. In DLD-1 the percentage remaining drug was 30.99% 
and 40.67% in SCS and spheroids, respectively.  
 
3.4. Mathematical model: 
The results obtained using the mathematical model, shown in Figures 4 and 5, reproduce 
qualitatively most of the features in the experimental data and distinguish between SCS and 
spheroid data. The simplicity of the model precludes it from being able to reproduce the 
decrease in intracellular drug concentrations from their high early values in the SCS uptake 
experiments as seen in Figures 4 and 5.  In particular, the high intracellular drug 
concentrations visible in the first 30-60 minutes of the SCS uptake experiments are not 
approximated well by the simulations; by contrast, the model recapitulates the observed 
concentration time variation for the spheroids reasonably well. The results for DLD-1 do 
show a very rapid initial increase in intracellular concentrations, but it is much smaller in 
magnitude than seen in the experiments. For DLD-1, the simulations slightly overestimated 
the SCS extracellular efflux concentrations and underestimate the spheroid extracellular 
efflux concentrations, but otherwise fit well to the experimental data. For MCF-7, the fits also 
qualitatively match the experimental data, though the intracellular concentrations obtained 
from the simulations slightly overestimate the uptake data and underestimate the efflux data. 
Note that the data have been fitted with both a standard least squares fit (shown in Figures 4 
and 5) and a χ2 fit (Supplementary material, Annex 1). There were no significant qualitative 
differences between the two sets of results. The discrepancies between the observed data 
and model fits for the SCS data are informative; it is clear that the initial very rapid uptake of 
drug in the SCS is not described accurately by simple first-order kinetic processes which are 
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assumed in the model and that an active transport mechanism is more likely, with higher-
order terms playing a leading role. Conversely, the agreement between the model and 
experiment seen in the spheroids, arguably of more relevance in tumours in-vivo, confirms 
that the dominant drug transport processes in the spheroid can be reasonably approximated 
by first order kinetic/diffusive transport mechanisms.  
 
4.0. Discussion 
We developed a methodology to study drug uptake and efflux in vitro in 2D and 3D models. 
For palbociclib we observed very high intracellular drug concentrations compared to the 
external media drug treatment concentration, with especially rapid uptake in SCS. The 
mathematical model we developed was able to reproduce most of the features of the 
experimental data.  
Palbociclib uptake experiments showed an initial rapid uptake rate in SCS, with slower 
uptake in spheroids occurring over 2 hours. In contrast, palbociclib efflux was much slower. 
Notably, intracellular Cmax in both SCS and spheroids was up to 32 times higher than the 
external media concentration. There are a number of potential hypotheses to explain this 
unusual pattern of drug uptake and efflux, such as active uptake or facilitated transport of the 
drug across the cell membrane, and very high non-target specific intracellular protein 
binding. Indeed, palbociclib has high peripheral tissue and protein binding, evidenced by its 
very large volume of distribution (EMA, 2016). When palbociclib crosses the cell membrane 
it quickly binds intracellular components leaving a low concentration of free, unbound drug. 
Drug will, therefore, continue to move into the cell until equilibrium is reached between the 
free intracellular drug concentration and the media, leading to accumulation inside the cells. 
In spheroids uptake is much slower as it is likely that intracellular binding saturation must be 
reached across several layers of cells. The less pronounced differences in efflux between 
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single cells and spheroids, when compared to uptake, could be explained by a slow 
intracellular unbinding rate.   
There are differences between the data obtained for MCF-7 and DLD-1; the uptake of 
palbociclib is more prominent in MCF-7, reaching a Cmax three times higher than in DLD-1. 
Potential differentials in transporter protein expression between the cell lines are the most 
likely explanation for this observation; indeed, the presence of an efflux transporter may 
explain why efflux equilibrium is reached more rapidly in DLD-1 cells. Palbociclib is a known 
substrate of the efflux transporter Pgp and breast cancer resistance protein (De Gooijer et 
al., 2015; Parrish et al., 2015); we have not yet explored the different transporters expressed 
in these two cell lines but this would benefit from further study. 
The experimental data are largely supported by the mathematical modelling. Specifically, the 
parameter values obtained and the model simulations suggest that binding is more rapid 
than unbinding. As in the experiments, the intracellular concentrations of bound drug at 
steady state in the uptake model simulations are much higher than the initial concentration of 
drug in the extracellular media (27 times higher for MCF-7, 6 times higher for DLD-1). These 
high concentrations are reached quite rapidly; hence, the binding in our model must be 
rapid, as higher intracellular concentrations than those in the external media could not be 
achieved by passive transport across the cell membrane alone and there is no facilitated 
membrane transport in our simple mathematical model. Moreover, the nature of the efflux 
data requires at least one process to act over a period of hours; only slow unbinding can 
give the slow decrease in intracellular efflux concentrations because the initial rapid rise in 
the extracellular concentrations suggests that membrane transport is rapid. This is more 
pronounced in the simulations of the DLD-1 data, despite the MCF-7 data signifying much 
faster membrane transport (according to the fitted values of k1). The slowest process (i.e. 
unbinding) is faster for MCF-7; therefore, the single-cell simulations settle more rapidly to an 
equilibrium state, most noticeably in the efflux experiments. However, the ratio of binding to 
unbinding rates is significantly higher for DLD-1 and consequently the equilibrium is closer to 
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saturation in the uptake experiments with C3, the bound drug concentration, reaching 
approximately 0.6% of C0 at steady state for MCF-7 compared to approximately 85% for 
DLD-1. 
The model for the spheroid data allows for spatial variation of drug concentrations within 
each spheroid. For the DLD-1 extracellular efflux data, a rapid initial increase suggests that 
transport within the spheroid is rapid, allowing unbound drug to escape quickly. This is 
followed by a slower process in which the bound drug starts to leave the spheroid. A 
consequence of this rapid intra-spheroid transport is that the model simulations suggest that 
the SCS and spheroid drug concentrations should both move towards equilibrium at a similar 
rate when considering uptake. In contrast, the MCF-7 data suggest much slower transport 
within the spheroid, so both uptake and efflux occur more slowly in spheroids than in SCS. 
This may, in part, be due to the binding of drug in the periphery of the spheroids delaying the 
transport of drug to their centres. In the simulations, this difference is a consequence of a 
much lower diffusion rate (Supplementary material, Annex 1, Table 1) computed when the 
model parameters are fitted to the MCF-7 data. When a χ2 fit is used, slower uptake and 
efflux is again seen in spheroids for MCF-7, but with this parameterisation it is a higher 
binding rate that induces this behaviour in combination with relatively slow diffusion. This 
provides some support to the hypothesis that high protein binding might explain the 
differences between the single cell and spheroid data, though the model also suggests that 
slow diffusive transport of the drug within the spheroid would affect the concentration profiles 
in a similar way. 
It is difficult to compare our results with the clinical PK parameters of palbociclib as 
intratumoural concentrations of palbociclib have not been reported in this setting. Moreover, 
our exposure concentration of 0.1µM should be seen as an artificial representation of steady 
state extracellular palbociclib concentrations based on reported clinical plasma Cmax values. 
Nevertheless, intratumoural palbociclib concentrations from in vivo experiments with breast 
cancer xenografts have been reported. There was, however, no correlation of plasma and 
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tumour concentrations as the mice bearing breast cancer xenografts for each measurement 
were treated with different palbociclib doses. In preclinical studies palbociclib intratumoural 
concentrations have been reported to be 25,163ng/gr (56.2μM) at 6 h after an oral dose of 
100mg/kg, and plasma Cmax of 48ng/ml (0.11μM) after a dose of 2mg/kg (Nguyen et al., 
2010; Smith et al., 2011). Human plasma Cmax from a palbociclib phase I study was 
97.4ng/ml (0.21μM) in a multiple dose schedule, but again tumour palbociclib levels were not 
measured (Flaherty et al., 2012). The high volume of distribution in clinical data supports, 
however, the high intracellular binding of palbociclib. 
 
Similar experiments have been undertaken with 5-fluorouracil (5FU), a drug with contrasting 
physicochemical properties to palbociclib, being highly polar with low protein and tissue 
binding. Images of radiolabelled 5FU showed very rapid uptake in spheroids within a few 
minutes (Nederman and Carlsson, 1984). Our 5FU uptake and efflux experiments (data not 
shown) are consistent with this previous publication, showing no difference between SCS 
and spheroids with similar intracellular and extracellular concentrations at Cmax and steady 
state (Jove et al., 2017). In contrast, studies undertaken with doxorubicin, a drug with 
physicochemical properties more similar to palbociclib, also showed quicker drug uptake in 
monolayers than in spheroids (Shan et al., 2018; Sutherland et al., 1979).  
Our results demonstrate the importance of a drug’s physicochemical properties in 
penetration and distribution within cancer cells. The results obtained using the mathematical 
model provide additional support for the hypotheses derived from the experimental data 
regarding the mechanisms that govern the dynamics of palbociclib intratumoural PK. It 
should be noted that in vitro models do not incorporate other factors typically affecting drug 
delivery in vivo, such as tumour stroma or vasculature and our mathematical model omits 
the effects of active transport, blood supply and interstitial fluid pressure. The 
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parameterisation itself determines how features in the experimental data are interpreted by 
the model.  
Arguably, the most striking data from this study relate to the large intracellular concentrations 
that accumulate rapidly after drug exposure. As drugs are assessed in vitro for their 
cytotoxicity or inhibitory effect, as expressed by an IC50, the implications of the intracellular 
concentrating effect we have seen could be important, with potential consequences for the 
translation of IC50 values into clinical efficacy. If intracellular concentrations in vitro are 
significantly higher than treatment concentration, actual IC50 values for some drugs may be 
much higher than previously thought. This may potentially lead to treatment failures due to 
sub-optimal dosing. We anticipate that, although some improvements are warranted as more 
data becomes available, the mathematical model developed here may be used to gain 
insights into the mechanisms underpinning the data and to obtain accurate predictions of the 
movement of drugs through tissue based on plasma concentrations. It is also anticipated 
that this will assist extrapolation from plasma PK data to tumour concentrations, estimating 
tumour PK data without the need for repeat tumour biopsy. 
In conclusion, these are the first in vitro models of drug uptake and efflux for palbociclib and 
together with the mathematical model they are useful to understand palbociclib intratumoural 
distribution. They could potentially be applied to other drugs to elucidate their intratumoural 
PK, facilitating improvements in drug delivery and ultimately treatment efficacy. 
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Legends for Figures: 
Figure 1. A representative western blot of CDK4 (30kDa), Rb (110kDa) and pRb 
phosphorylated at Serine 780 (110kDa) expression in MCF-7 and DLD-1 cell lines. Negative 
CDK6 (37kDa) not shown.  
Figure 2. Palbociclib uptake over time in SCS (A) and spheroids (B) for MCF-7 and DLD-1 
cell lines when exposed to media containing 0.1μM palbociclib for up to 480 min. Error bars 
represent range (n = 3). Difference in MCF-7 and DLD-1 Cmax  for SCS and spheroids, Man 
Whitney Test p=0.035 and 0.1 respectively. 
Table 1. Summary of uptake data for MCF-7 and DLD-1 in SCS and spheroids. Values in 
brackets represent respective confidence intervals of 95 % (IC95%). Difference in SCS and 
spheroid Cmax  not significant (MCF-7 p=0.36, DLD-1 p=0.2). Difference in MCF-7 and DLD-1 
Cmax  SCS p=0.035 (significant), spheroids p=0.1 (not significant). Difference in DLD-1 and 
MCF-7 AUCSCS p=0.035 (significant), AUCspheroids p=0.1 (not significant). 
Table 2. Summary of efflux data for MCF-7 and DLD-1 in SCS and spheroids. Values in 
brackets represent respective confidence intervals of 95 % (IC95%).  
Figure 3. Palbociclib efflux over time in SCS (A and B) and spheroids (C and D) for MCF-7 
and DLD-1 cell lines after a 1 hour (SCS) or 2 hour (spheroids) exposure to media 
containing 0.1μM palbociclib prior to incubation in drug-free media. Data points represent 
intracellular concentration of palbociclib remaining at each time point (IN) and effluxed 
palbociclib measured in the media (OUT). Error bars represent range (n = 3).  
Figure 4. Least squares 5-parameter fitting model to all cell and spheroids data for MCF-7. 
The graphs represent uptake intracellular concentration for SCS (A) and spheroids (D), 
efflux intracellular concentration for SCS (B) and spheroids (F) and efflux extracellular 
concentration measured in the media for SCS (C) and spheroids (D). Data points are 
experimental data as shown in Figures 2 and 3. The line on each plot represents the 
mathematical simulation.  
Figure 5. Least squares 5-parameter fitting model to all cell and spheroids data for DLD-1. 
The graphs represent uptake intracellular concentration for SCS (A) and spheroids (D), 
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efflux intracellular concentration for SCS (B) and spheroids (F) and efflux extracellular 
concentration measured in the media for SCS (C) and spheroids (D). Data points are 
experimental data as shown in Figures 2 and 3. The line on each plot represents the 
mathematical simulation.  
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Table 1. 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
  11 
Uptake uptake Tmax C max C max AUC
nM/min min µM pmol/mg µM.h
3.22µM 53.5 509
(2.50-3.93) (43.5-63.5) (237.7-779.8)
1.28 15.29 169
(0.38-2.19) (7.92-22.6) (29.73-308.3)
2.91 31.6 624
(2.08-3.73) (21.8-41.4) (428.1-819.3)
0.68 8.11 153
(0.14-1.22) (2.30-13.9) (66.29-324.3)
MCF-7 SCS 631.1 10
DLD-1 SCS 187.3 10
MCF-7 spheroids 31.2 240
DLD-1 spheroids 15.6 120
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Table 2. 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
  26 
Efflux Efflux
Time to efflux re- 
equilibration 
the percentage of 
intracellular palbociclib 
remaining at 480min
(nM/min) (min) (%)
45.1
(26.1-64.2)
31
(0-68.54) 
70.76
(65.65-75.87) 
40.67
(31.11-50.27)
MCF-7 cells 2.3 480
DLD1 cells 0.08 240
MCF-7 spheroids 2.1 >480
DLD1 spheroids 0.1 240 to 360
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pRb (Ser780) Rb 
DLD-1  MCF-7 
CDK4 (30kDa) 
β-actin (42kDa) 
130 
72 
55 
28 
36 
95 
Rb + Phos-Rb 
(Ser780) (110kDa) 
DLD-1  MCF-7 
36 
55 DLD-1 MCF-7 
β-actin (42kDa) 
Figure 1. A representative western blot of CDK4 (30kDa), Rb (110kDa) 
and pRb phosphorylated at Serine 780 (110kDa) expression in MCF-7 
and DLD-1 cell lines. Negative CDK6 (37kDa) not shown.  
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Figure 2.  43 
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Figure 3.  65 
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Figure 4.  84 
 85 
 86 
 87 
 88 
 89 
 90 
 91 
 92 
 93 
 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
 105 
 106 
 107 
  108 
A 
B 
C 
D 
E 
F 
This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on June 12, 2019 as DOI: 10.1124/jpet.119.256693
 at A
SPET Journals on June 19, 2019
jpet.aspetjournals.org
D
ow
nloaded from
 
 36 
 
 109 
Figure 5. 110 
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